Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | GMNN | O75496 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apaxifylline SCHEMBL194999 | 1.00 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL4621677 | 0.87 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| 1,3-Dipropyl-8-Cyclopentylxanthine [Dpcpx] SCHEMBL382422 | 0.85 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL4623484 | 0.84 | ADORA1 (1.00) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8835935 | 0.83 | ADORA1 (0.73) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8836119 | 0.83 | ADORA1 (0.73) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8902076 | 0.82 | ADORA1 (0.70) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL8902082 | 0.82 | ADORA1 (0.70) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL9729354 | 0.82 | ADORA1 (0.90) | ADORA1ADORA2AADORA2BADORA3MEN1 | |
| SCHEMBL9729018 | 0.82 | ADORA1 (0.90) | ADORA1ADORA2AADORA2BADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9555037-B2 | Method of using vasoconstrictive agents during energy-based tissue therapy | COVIDIEN AG | 2017-01-31 | — | — | US | claimed |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | SHERWOOD SERVICES AG (CH) | 2016-06-02 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-8202242-B2 | Method of using vasoconstrictive agents during energy-based tissue therapy | COVIDIEN AG (CH) | 2012-06-19 | — | — | US | claimed |
| US-7767686-B2 | Method of using adenosine receptor blockers during tissue ablation | COVIDIEN AG (CH) | 2010-08-03 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20080275068-A1 | administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone | COVIDIEN AG (CH) | 2008-11-06 | — | — | US | claimed |
| US-20080045551-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN ADENOSINE A1 ANTAGONIST AND A RADIOCONTRAST MEDIA | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| EP-1870093-A1 | Pharmaceutical combination comprising adenosine A1 receptor antagonists and radiocontrast media | Solvay Pharmaceuticals GmbH (DE) | 2007-12-26 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| CN-1564688-A | Methods of treating pulmonary disease | BIOGEN IDEC INC (US) | 2005-01-12 | — | — | CN | claimed |
| US-20040259889-A1 | Methods of treating pulmonary disease | BIOGEN IDEC MA INC. | 2004-12-23 | — | — | US | claimed |
| EP-1429775-A1 | METHODS OF TREATING PULMONARY DISEASE | Biogen Idec MA Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003022284-A1 | METHODS OF TREATING PULMONARY DISEASE | BIOGEN IDEC MA INC. (US) | 2003-03-20 | — | — | WO | claimed |
| US-5696124-A | Xanthine derivatives with adenosine-antagonistic activity | BOEHRINGER INGELHEIM KG (DE) | 1997-12-09 | — | — | US | claimed |
| EP-0374808-B1 | Xanthin derivatives having an adenosin-antagonist activity | BOEHRINGER INGELHEIM KG (DE) | 1996-04-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259889-A1 | Methods of treating pulmonary disease | ADORA1, ADORA2A, TBXA2R | ADORA1 1/4885ADORA2A 2/4885ADORA2B 5/4885 |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | PLAT, TEK, PLG | ADORA1 503/4885ADORA2A 271/4885ADORA2B 339/4885 |
| US-20080275068-A1 | administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.